Gain Therapeutics (NASDAQ:GANX) Announces Quarterly Earnings Results

Gain Therapeutics (NASDAQ:GANX) issued its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03, FiscalAI reports.

Gain Therapeutics Price Performance

Shares of GANX stock opened at $1.89 on Friday. The stock’s fifty day moving average is $2.13 and its 200-day moving average is $2.36. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.52 and a current ratio of 2.52. The stock has a market capitalization of $72.69 million, a PE ratio of -3.10 and a beta of -0.03. Gain Therapeutics has a 52 week low of $1.41 and a 52 week high of $4.34.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in GANX. Sprott Inc. bought a new stake in Gain Therapeutics during the 4th quarter worth about $39,000. Commonwealth Equity Services LLC acquired a new position in shares of Gain Therapeutics during the fourth quarter worth approximately $41,000. Millennium Management LLC acquired a new position in shares of Gain Therapeutics during the fourth quarter worth approximately $45,000. JPMorgan Chase & Co. bought a new stake in shares of Gain Therapeutics during the third quarter valued at approximately $47,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Gain Therapeutics during the fourth quarter valued at approximately $47,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on GANX. Roth Mkm reaffirmed a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a report on Friday, December 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.